Dr Reddy’s Laboratories and Gilead Sciences have signed a licensing agreement. This pact involves investigational once-yearly lenacapavir for HIV prevention. The agreement facilitates manufacturing and supply planning for 120 countries. This collaboration builds upon a previous pact for twice-yearly lenacapavir.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.